H.R. 5534 Passed: Lifetime Medicare Coverage of Immunosuppressant for Kidney Recipients - American Transplant Foundation
Frontiers | Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial - American Journal of Transplantation
Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis | PNAS
Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation - ScienceDirect
Cancer Risk Among Immunosuppressed Populations - NCI
Targeted Therapy and Immunosuppression in the Tumor Microenvironment: Trends in Cancer
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy | Nature Reviews Clinical Oncology
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text
Transplantology | Free Full-Text | Strategies to Improve Immune Suppression Post-Liver Transplantation: A Review
PDF) High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy
Role of tumor microenvironment in EGFR-mutated NSCLC in influencing... | Download Scientific Diagram
Patient-centred approaches for the management of unpleasant symptoms in kidney disease | Nature Reviews Nephrology
High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy | SpringerLink
Clinical use of dendritic cells for cancer therapy - The Lancet Oncology
MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms | Oncogenesis
Systemic immunity in cancer | Nature Reviews Cancer
Frontiers | Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy - ScienceDirect
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? - ScienceDirect
Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer - ScienceDirect
Frontiers | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Immunocompromised Populations
Pathogens | Free Full-Text | Comprehensive Overview of Toxoplasma gondii-Induced and Associated Diseases
